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Background: An increasing number of patients (pts) have refractory angina (RA) despite optimal medical management that is not amenable for 
revascularization. RA pts have a relatively low mortality rate (<4%/year) but significant limitations in their quality of life. The Ranolazine RA Registry 
Trial was designed to evaluate the safety, tolerability and effectiveness of ranolazine in RA patients.
methods: We enrolled 153 consecutive RA pts treated with ranolazine as part of an extensive ongoing prospective RA registry in a dedicated 
RA clinic. Pts were contacted at 1, 6 and 12 months to obtain angina class, medication use, hospital readmission, myocardial infarction, 
revascularization, and death.
results: Of the 153 pts enrolled (mean age 64.7 years; 75% male), 141 (92.2%) have completed 1 year of follow-up. For patients completing 1 
year follow-up, 92 (65.3%) remained on ranolazine (90.7% 500 mg BID). Reasons for discontinuation were side effects (n=21), revascularization 
(n=7), cost (n=5), ineffective (n=8), cost and ineffective (n=4), death (n=2), unknown (n=2). The proportion of pts with ≥2 class improvement in 
angina was higher for those remaining on ranolazine compared to those with discontinued use (51.8% vs. 23.1%; p=0.003) (Table).
 
conclusions: Ranolazine is an effective anti-anginal therapy in patients with refractory angina. At one year, 65% of patients remained on ranolazine 
with the major limitations being side effects, cost, suboptimal effectiveness and progression of disease.
